Solid tumours with confirmed NTRK gene fusion

The PBS subsidises larotrectinib for patients with solid tumours with confirmed neurotrophic tropomyosin receptor kinase (NTRK) gene fusion.

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with larotrectinib under the National Health Act 1953, section 85 for patients with solid tumours with confirmed NTRK gene fusion.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing larotrectinib.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised larotrectinib to treat solid tumours with confirmed NTRK gene fusion can be made either in:

All written applications must include:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised larotrectinib to treat solid tumours with confirmed NTRK gene fusion can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 2 August 2024.
QC 62768